<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04974164</url>
  </required_header>
  <id_info>
    <org_study_id>CoronaVacTND</org_study_id>
    <nct_id>NCT04974164</nct_id>
  </id_info>
  <brief_title>Effectiveness of COVID-19 Vaccine for Prevention of COVID-19 in the Dominican Republic</brief_title>
  <official_title>Effectiveness of COVID-19 Vaccine (Vero Cell), Inactivated (CoronaVac) for Preventing Symptomatic SARS-CoV-2 Infections and Hospitalizations in the Dominican Republic - Test-Negative Case-Control Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sinovac Research and Development Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sinovac Biotech Co., Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a multisite ,grouped test-negative case-control , phase Ⅳ clinical trial of an&#xD;
      inactivated SARS-CoV-2 vaccine (CoronaVac) manufactured by Sinovac Research and Development&#xD;
      Co., Ltd.The purpose of this study is to estimate the protective effectiveness of complete&#xD;
      vaccination (measured ≥14 days after the second dose) of CoronaVac against symptomatic&#xD;
      SARS-COV-2 infections ,COVID-19 hospitalizations and severe cases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is a multisite,grouped test-negative case-control , phase Ⅳ clinical trial in&#xD;
      population aged 18 years and older. The experimental vaccine will be manufactured by Sinovac&#xD;
      Research and Development Co.,Ltd.The study is planned to be carried out in ten (10) selected&#xD;
      hospitals and their catchment communities in five provinces of the Dominican Republic (DR):&#xD;
      National District, La Altagracia, Puerto Plata, Santiago, and Santo Domingo from July 1, 2021&#xD;
      to April 30, 2022 . A total of 1400 subjects will be enrolled with 700 estimated clinic cases&#xD;
      who are diagnosed as SARS-CoV-2 infection by real-time polymerase chain reaction (RT-PCR);&#xD;
      and 700 estimated clinic controls who have a negative RT-PCR test.And subjects will receive&#xD;
      two doses of vaccine for primary immunization .&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 17, 2021</start_date>
  <completion_date type="Anticipated">April 17, 2022</completion_date>
  <primary_completion_date type="Anticipated">November 17, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Protective effectiveness of complete vaccination of CoronaVac against symptomatic SARS-COV-2 infections</measure>
    <time_frame>Day 14 after the second dose</time_frame>
    <description>SARS-COV-2 infections confirmed by real-time polymerase chain reaction (RT-PCR) in newly collected nasopharyngeal swab sample among patients visiting the ER in the study hospitals during the study period without a positive RT-PCR test in the preceding 90 days period</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Protective effectiveness of complete vaccination of CoronaVac against COVID-19 hospitalizations and severe cases.</measure>
    <time_frame>Day 14 after the second dose</time_frame>
    <description>Severe disease (including death), defined as a score &gt;5 in terms of WHO clinical progression scale due to SARS-CoV-2 infection</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To profile the circulating strains of SARS-CoV-2 in DR</measure>
    <time_frame>Day 14 after the second dose</time_frame>
    <description>Circulating strains of SARS-CoV-2 in DR</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>COVID-19</condition>
  <arm_group>
    <arm_group_label>Clinic cases group</arm_group_label>
    <description>Those with a positive RT-PCR test will be the test-positive cases or clinic cases (approximate N=700)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Clinic controls group</arm_group_label>
    <description>Those with a negative RT-PCR test will be the test-negative cases or clinic controls (N=700)</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Inactivated COVID-19 Vaccine</intervention_name>
    <description>Each vial contains 0.5 mL (a single dose) and contains 600SU of inactivated SARS-CoV-2 virus antigen</description>
    <arm_group_label>Clinic cases group</arm_group_label>
    <arm_group_label>Clinic controls group</arm_group_label>
    <other_name>CoronaVac</other_name>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      All laboratory antibody and RT-PCR tests will be conducted in the central study lab&#xD;
      (Laboratorio de Referencia) in the capital city.Antibody testing on the blood sample will be&#xD;
      performed to test anti-SARS-CoV-2 IgGantibody,the remaining serum will be stored in -70℃ (or&#xD;
      -40℃) freezer；RT-PCR testing on nasopharyngeal swab will be performed to assess the presence&#xD;
      of SARS-CoV-2 RNA；SARS-CoV-2 sequencing testing，the remaining swab for PCR testing will be&#xD;
      stored in -70oC (or -40oC) freezer for SARS-CoV-2 sequencing testing to assess protection&#xD;
      against variants when the test is available.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The participants will be recruited from clinic patients in 10 study hospitals in five&#xD;
        provinces. Patients who visit the emergency room (ER), fever or respiratory disease clinics&#xD;
        to seek diagnosis or health care for severe acute respiratory infection symptoms or signs&#xD;
        and are considered as suspected cases of SARS-CoV-2 based in DR national COVID-19 clinical&#xD;
        guideline will be invited to participate in the study, and 1400 clinic participants will be&#xD;
        enrolled, 140 from each hospital.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Aged ≥18 years;&#xD;
&#xD;
          -  Permanent residents of study provinces;&#xD;
&#xD;
          -  Able and willing to provide informed consent to participate in the study;&#xD;
&#xD;
          -  Able and willing to provide nasopharyngeal swab and venous blood sample;&#xD;
&#xD;
          -  Able and willing to complete a questionnaire survey for collecting information on&#xD;
             histories of COVID-19 vaccination and disease;&#xD;
&#xD;
          -  Considered as suspected cases of SARS-CoV-2 infections by the physicians in the study&#xD;
             clinics according to DR national protocol.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eddy Perez-Then, Doctor</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ministry of Health</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eddy Perez-Then, Doctor</last_name>
    <phone>+1 (809) 682-8849</phone>
    <phone_ext>(809) 876-7760</phone_ext>
    <email>conabios_rd@yahoo.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Moscoso Puello Hospital</name>
      <address>
        <city>Bella Vista</city>
        <state>Distrito Nacional</state>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Felix Maria Goico Hospital</name>
      <address>
        <city>Villa Francisca</city>
        <state>Distrito Nacional</state>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Gral Esp Ntra Sra dela Alt</name>
      <address>
        <city>Higuamo</city>
        <state>La Altagracia</state>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital IMG</name>
      <address>
        <city>Higuey</city>
        <state>La Altagracia</state>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Centro Médico Bournigal</name>
      <address>
        <city>San Felipe de Puerto Plata</city>
        <state>Puerto Plata</state>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Ricardo Limardo</name>
      <address>
        <city>Sosúa</city>
        <state>Puerto Plata</state>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>JoséM.Cabral V Báez</name>
      <address>
        <city>Puñal</city>
        <state>Santiago</state>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Clinica Unión Medica del Norte</name>
      <address>
        <city>Santiago de los Caballeros</city>
        <state>Santiago</state>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Fuerza AéreaDr Ramón Lara</name>
      <address>
        <city>Los Alcarrizos</city>
        <state>Santo Domingo</state>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Marcelino Vélez Santana</name>
      <address>
        <city>San Antonio de Guerra</city>
        <state>Santo Domingo</state>
        <country>Dominican Republic</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Dominican Republic</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>July 22, 2021</study_first_submitted>
  <study_first_submitted_qc>July 22, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2021</study_first_posted>
  <last_update_submitted>October 22, 2021</last_update_submitted>
  <last_update_submitted_qc>October 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>COVID-19</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

